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Hematopoiesis proceeds from a bone marrow resident population of stem cells responsible 
for generation of all lineages within the blood. Distinct molecular programs within hematopoietic stem 
cells regulate maintenance of this population under homeostatic conditions, however the coordination 
of these programs remains largely undefined. DNA methylation is an epigenetic means of gene 
regulation in a mammals carried out by a family of DNA methyltransferases. Of these, the de novo 
methyltransferase is highly expressed in hematopoietic stem cells as compared  to other members of 
this family and somatic mutations in DNMT3b lead to a syndrone characterized by immunodeficiency. 
Therefore we hypothesized that DNMT3b regulates hematopoietic stem cells via its ability to 
methylate DNA. By knock-down of DNMT3b with a retrovirally delivered shRNA or Cre mediated 
recombination of floxed DNMT3b alleles work presented in this thesis demonstrates a critical role for 
DNMT3b in hematopoiesis in mice. Loss of DNMT3b leads to limited reconstitution of hematopoiesis 
in irradiated recipients associated with a proliferative defect in vitro and a failure of hematopoietic 
stem cell self-renewal in vivo. Targeted deletion of DNMT3b in hematopoietic stem cells leads to 
decreased engraftment following transplantation and decreased proliferation in vitro. DNMT3b’s 
function in hematopoietic cells requires the methyltransferase activity of the enzyme and the defects 
in hematopoiesis are associated with loss of DNA methylation and decreased expression of MLL. 
Therefore DNMT3b is necessary for maintenance of the proliferative ability and engraftment capacity 
of hematopoietic cells and hematopoiesis is dependent upon appropriate DNA methylation.  
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1.0 INTRODUCTION 
 
 
 
 
Somatic stem cells are largely responsible for tissue repair and regeneration over the lifetime of an 
individual.  Hematopoietic stem cell  transplantation is currently being used for the treatment of 
congenital deficiencies and an increasing number of malignant diseases[1]. Hematopoietic stem cells 
have become increasingly useful with the advent of efficient isolation techniques and with their ability 
to acquire unique functions through genetic engineering.  However, despite the enthusiasm 
surrounding hematopoietic stem cell biology and therapeutics, the full potential of hematopoietic stem 
cell manipulation in vitro has yet to be fully realized and is highly dependent upon the development of 
technologies that enhance specific characteristics of these cells. The ultimate success of 
hematopoietic stem cell expansion in vitro and efficient repopulation of the entire hematopoietic and 
immune system in vivo will require a greater understanding of the molecular mechanisms 
coordinating hematopoietic stem cell self-renewal and differentiation. As hematopoietic stem cell 
function plays a vital role in hematopoiesis over an individual’s lifetime, understanding the biological 
and functional regulation of these cells is of paramount importance. 
Epigenetic regulation of gene expression by DNA methylation has been shown to play a role 
during the differentiation and self-renewal of a number of pluripotent cell types[2-4]. DNA methylation 
in mammals is carried out by a family of DNA methyltransferases: DNMT1, DNMT3a, and DNMT3b. 
Loss of DNMT1 has been shown to limit hematopoietic stem cell function[5] and DNA methylation is 
necessary for B cell development from hematopoietic progenitor cells[6]. DNMT3b is highly 
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expressed in hematopoietic stem cells[7, 8] and inherited mutations in this gene in humans are 
associated with a syndrome characterized by immunodeficiency[9], however a unique role for 
DNMT3b in hematopoietic stem cells has not been determined. To that end this thesis addresses the 
role of DNMT3b in hematopoietic stem cells. Knockdown of DNMT3b by a retrovirally-delivered 
shRNA or by Cre mediated recombination of floxed DNMT3b alleles led to limited hematopoietic 
stem engraftment in irradiated recipients that was associated with loss of the self-renewal ability of 
hematopoietic stem cells. DNMT3b function in hematopoietic cells appears to require its 
methyltransferase activity and improper methylation of the trithorax homolog MLL (mixed lineage 
leukemia) gene and subsequent down-regulation of its homeobox targets  may underlie this defect. 
Elucidation of the role of DNMT3b in hematopoiesis may allow for future studies addressing the role 
DNA methylation plays in hematopoietic stem cell regulation as well as potential targets for ex vivo 
manipulation to enhance stem cell engraftment and function following transplantation. 
 
 
 
 
1.1 HEMATOPOIETIC STEM CELL ISOLATION AND NICHE 
 
 
1.1.1 Hematopoietic Stem Cell Enrichment 
Hematopoietic stem cells are a rare population of bone marrow cells responsible for generation of all 
lineages within the blood over the lifetime of an organism. The availability of monoclonal antibodies 
and the ability to isolate cells by fluorescence activated cell sorting (FACS) has allowed for the 
successful enrichment of bone marrow cells containing nearly all the hematopoietic reconstituting 
ability of the bone marrow[10]. Combinatorial strategies involving selection for the thymocyte marker 
Thy-1 and depletion of cells expressing differentiated cell markers was shown to enrich for 
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approximately 0.1% of adult mouse bone marrow that still contained the entire colony forming ability 
in the spleen[11]. This population could be further enriched by selecting for cells expressing Stem 
Cell Antigen-1 (Sca-1), a member of the Ly-6 family[12] discovered in a screen of pre-T cell 
hybridoma cell surface expression molecules[10], and c-kit, the cell surface receptor for stem cell 
factor[13]. Depletion of bone marrow cells expressing markers of mature hematopoietic lineages 
(B220+ B cells, CD3+, CD4+, or CD8+ T cells, Gr-1+ and/or CD11b+ myeloid cells, and Ter-119+ 
erythroid precursors) as well as positive selection for Sca-1 and c-kit expression (LKS cells) allows for 
enrichment of stem cell activity from approximately 1 in 20,000 whole bone marrow cells to greater 
than 1 in 10 based on competitive long-term repopulation in irradiated recipients[14]. Long term 
repopulating hematopoietic stem cells in mice can be further enriched based on a low level of CD34 
expression, which represents about 1 in 5 LKS cells[15]. When transplanted into irradiated recipients 
only long term hematopoietic stem cells (LT-HSCs) are capable of engraftment greater than 3 
months owing to their sustained self-renewal potential. Conversely, short term hematopoietic stem 
cells (ST-HSCs), that are CD34+LKS, are only able to maintain their reconstituting ability for 
approximately two months[15]. Remarkably as few as one murine HSC is able to efficiently 
reconstitute the hematopoietic system of a lethally-irradiated syngeneic recipient [16-22] although not 
every transplanted recipient will show engraftment[23].   
More recently, based on microarray data, the signaling lymphocyte activation molecule 
(SLAM) marker CD150 has been shown to be uniquely expressed on hematopoietic stem cells with 
long-term engraftment ability as compared to multipotent progenitors with limited self-renewal. 
Combination of CD150 expression with absence of a second SLAM marker CD48 (CD150+CD48-) 
can allow for equally efficient enrichment of hematopoietic stem cells from the bone marrow as 
compared to combinatorial strategies based on LKS and CD34 expression[24]. The SLAM markers 
have proven useful for immunohistochemical staining of hematopoietic stem cells with the bone 
marrow and further elucidation of their relationship with the bone marrow niche[24]. 
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Intermediate progenitors with limited self-renewal potential can also be isolated from the bone 
marrow based on their immunophenotype as summarized in Figure 1-1. Most transiently 
repopulating progenitors express c-kit, but lack Sca-1 expression, and do not express lineage 
markers. Multipotent or highly proliferative progenitors, as the name suggests, cycle rapidly, but lack 
the capacity for extended self-renewal and only transiently contribute to hematopoiesis when 
transplanted into irradiated recipients[25]. This population expresses the feline sarcoma virus (fms)-
like tyrosine kinase receptor Flt-3 and may largely contribute to a transient lymphoid reconstitution 
following transplantation[25]. All lymphoid cells arise for a common lymphoid progenitor that 
expresses the receptor for Il-7[26]. Myeloid cells are derived from a group of unique progenitors that 
can be isolated based on their expression of CD34 and Fc Receptor  (FcR) on the cell surface[27]. 
The most immature myeloid restricted progenitor is CD34+FcR lo and is named the common 
myeloid progenitor. This population of cells gives rise to distinct progenitor populations; granulocyte-
monocyte progenitors which are CD34+FcR hi and megakaryocyte erythrocyte progenitors which are 
CD34-FcR lo[27]. These lymphoid and myeloid progenitors then proceed to differentiate through a 
number of pro and blast-like cells based on their cellular immunophenotype and gene expression 
levels to the mature lineages of the hematopoietic system in the peripheral blood and hematopoietic 
organs. 
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1.1.2 Hematopoietic Niche 
Hematopoietic stem cells reside in a specialized niche within the bone marrow of adult mammals in 
close proximity to the endosteal surface (Figure 1-2). A functional relationship between the endosteal 
surface and cells with hematopoietic reconstituting ability was first indicated by the observation that 
the cells responsible for colony-forming units in the spleen (discussed in 1.2.1) reside near the 
endosteum as opposed to the central bone marrow[28] although these cells were later shown to be 
transiently reconstituting multipotent progenitors[14] that are relatively non-quiescent[28].  CFSE 
stained immunophenotypically defined hematopoietic stem cells have since been shown to migrate to 
within 12 cell diameters of the endosteal surface following transplantation[29]  as well as in close 
proximity to perivascular cells within sinusoids[24]. However, immunohistochemical staining of mouse 
bone marrow with SLAM markers failed to identify co-localization of this relatively pure hematopoietic 
stem cell population directly on the endosteum[24]. The endosteal surface of bone is lined with 
osteoblastic progenitors at varying degrees of differentiation which have been shown to play a role in 
hematopoietic stem cell maintenance. Expansion of osteoblastic cells by overexpression of a 
constitutively active parathyroid hormone receptor or exogenous administration of parathyroid 
hormone[30] or inactivation of bone morphogenic protein receptor type IA[31] leads to osteoblastic 
cell expansion and concomitant increase in hematopoietic stem cell pools. However acute depletion 
of osteoblastic cells by ganciclovir treatment of mice expressing thymidine kinase under the control of 
a collagen 1A1 promoter resulted in a more rapid and dramatic decrease in lymphoid progenitors, 
particularly B-cell progenitors, and a slow decrease in LKS cells [32, 33]. This data suggests that 
while osteoblasts can regulate hematopoietic stem cell pools this regulation may not require direct 
cell-to-cell contact between these two cell populations but may act through paracrine signaling or 
intermediate cell types and other cell types may play overlapping roles in the hematopoietic niche.  
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Osteoblastic cells have been shown to secrete a number of proteins necessary for 
hematopoietic stem cell maintenance or localization to the bone marrow.  Murine hematopoietic stem 
cells expressing the angiopoietin receptor Tie2 are quiescent and anti-apoptotic[34]. Treatment of 
bone marrow cells with angiopoietin in vitro enhances cobblestone formation on irradiated stromal 
cells, a surrogate marker of hematopoietic stem cell self-renewal, and maintains hematopoietic stem 
cells in a quiescent state in vivo[34]. Thrombopoietin, which has been shown to be secreted from 
endosteal osteoblastic cells, also promotes hematopoietic stem cell quiescence; loss of 
thrombopoietin or its receptor c-Mpl leads to hematopoietic stem cell depletion[35, 36]. In contrast to 
angiopoietin and thrombopoietin, osteopoietin negatively regulates hematopoietic stem cells; mice 
lacking osteopoietin have an increased frequency of hematopoietic stem cells in the bone 
marrow[37]. Although these three factors are produced by osteoblastic cells, multiple other cell types 
can also produce them, including the liver and kidney in the case of thrombopoietin[38]. Thus in the 
absence of studies involving targeted depletion of osteoblast-derived growth factors,  contribution to 
hematopoietic stem cell maintenance by osteoblasts via these growth factors remains 
controversial[38].  
Osteoclasts, sinusoidal perivascular cells, and bone marrow-resident mesenchymal stem 
cells may also play a role in the hematopoietic stem cell niche. Bone degradation by osteoclasts may 
destroy the endosteal niche leading to hematopoietic stem cell mobilization[39], i.e. enhanced 
hematopoietic stem cell cycling and increased presence of stem and progenitor cell types in the 
peripheral blood, lymph nodes, and spleen. Mice lacking the calcium receptor have been shown to 
have reduced bone marrow cellularity concurrent with increased progenitor mobilization suggesting 
that hematopoietic stem cell  lodging at the bone marrow is dependent on calcium ions[40] which are 
released by the activity of osteoclasts.  Hematopoietic stem cell homing near sinusoids may allow for 
rapid response of these cells to circulating cytokines[38]. Moreover perivascular cells within the 
sinusoid secrete CXCL12 which, by deletion of its receptor CXCR4, has been shown to maintain 
hematopoietic stem cells within the niche and their functionality in transplantation assays[41]. Nestin+ 
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mesenchymal stem cells have also been shown to closely associate with hematopoietic stem cells 
both in vivo and in vitro and provide a source for osteoblastic cells that further regulate hematopoietic 
stem cell homing and maintenance[42]. Thus while multiple cell types can regulate the hematopoietic 
niche, rigorous assessment of the function of the individual cells is lacking and redundancy in 
signaling to hematopoietic stem cells may underlie this compartment. 
 
 
 
 
1.2 HEMATOPOIETIC STEM CELL FUNCTION 
 
 
1.2.1 Historical Perspective 
The concept of a stem cell is derived from the field of evolutionary biology and the theory developed 
by Ernest Hackel in the 19th century that multicellular organisms were derived from a unicellular 
precursor, which was termed the German “Stamzelle”[43]. Hackel also proposed that this term 
applied to the fertilized embryo due to its ability to give rise to multiple distinct lineages and the term 
was subsequently extended to include germ line stem cells and hematopoietic precursors, as yet 
unidentified, in the bone marrow with similar properties[43].  
Although the ability of bone marrow transplantation to protect irradiated recipients from 
hematopoietic failure was known[44], the first identification of cells with this property occurred in 1961 
by Till and McCulloch with their observation of splenic colonies 10 days after bone marrow 
transplantation[45]. Till and McCulloch described hematopoietic precursors in terms of spleen colony 
forming units (CFU-S), a functional definition of the bone marrow that was shown to correlate with the 
ability of the marrow to protect transplanted recipients from hematopoietic failure[46].  The colonies 
were later shown, by chromosomal marking, to be derived from a single cell[47] as well as having the 
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capacity for self-renewal and multipotent differentiation[48], the two key properties of stem cells. 
When serially transplanted into irradiated recipients a decrease in the colony forming ability in the 
spleen was observed greater than that from aged mice suggesting an increased loss of stem cell 
function with serial transplantation as compared to aging[49]. Thus exhaustion of stem cell 
functionality is enhanced under the stress of serial transplantation and transplantation of these cells 
into irradiated recipients can reveal hematopoietic stem cell defects not readily apparent under 
homeostatic conditions. In addition early studies revealed  the stem cell compartment to be relatively 
quiescent such that cytotoxic agents that require progression through the cell cycle for their activity 
spare these quiescent hematopoietic stem cells and increase their proportion in the bone marrow[50, 
51]. This work completed before prospective isolation of hematopoietic stem cells was achieved, 
provided a functional definition of hematopoietic stem cells as a relatively quiescent population of 
bone marrow cells that can be activated to self-renew or differentiate to maintain homeostasis within 
the hematopoietic system. Despite the inability at the time to prospectively enrich for these cells from 
the bone marrow the key properties of stem cells had been described for blood-forming bone marrow 
cells laying a conceptual framework for future studies.   
 
 
1.2.2 Hematopoietic Stem Cell Assays 
The balance between the two key properties of hematopoietic stem cells, self-renewal and the ability 
to differentiate, can be described in terms of symmetric versus asymmetric division. In a symmetric 
division both daughter cells have the same phenotype, either that of the parental cell or a more 
differentiated progenitor. An asymmetric division yields one daughter cell of the same phenotype as 
the original cell and a more differentiated progenitor cell type.  Under physiological conditions, a 
balance exists between symmetric and asymmetric divisions to maintain both the stem cell pool and 
homeostasis within the hematopoietic system.  A relative increase in symmetric divisions yielding two 
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progenitor cells will deplete the stem cell pool causing HSC exhaustion. Conversely increased 
symmetric divisions yielding two stem cells will expand the HSC population.  
The gold standard assessment of hematopoietic stem cell functionality is the determination of 
the ability of these cells to recapitulate hematopoiesis when transplanted into irradiated recipients. 
Lethal irradiation of mice with a single 9 to 10 Gray dose will lead to hematopoietic failure and 
ultimately death of the mouse after approximately 3 weeks without bone marrow transplantation[52]. 
Transplantation experiments often employ bone marrow cells from knock-out mice or cells carrying 
floxed alleles of the gene of interest that can be deleted by inducing Cre recombinase expression 
with tamoxifen (ER-Cre)[53] or poly(dI-dC) (Mx1-Cre)[54]. Competitive bone marrow transplantation 
experiments involve transplantation of two populations of cells into one mouse. These populations 
can be identified based on the sex of the donor animal[55], retroviral marking of the populations[56], 
or by employing bone marrow cells from mice expressing different isoforms of the pan-hematopoietic 
marker CD45[57]. The latter methodology takes advantage of the ability to distinguish the source of 
the engrafted cells, as well as the recipient cells, by using flow cytometry analysis with antibodies for 
CD45.1 and CD45.2. The competitor cells allow for normalization of donor cell engraftment within 
each mouse and can also provide a source of rapidly reconstituting cells to overcome the time 
necessary for more immature stem cell populations to home and engraft within the bone marrow. 
Following transplantation, contribution of donor-derived cells to the peripheral blood is monitored 
monthly for 3 months in order to generate an accurate functional assessment of the most immature 
hematopoietic stem cells. Altered stem cell self-renewal, i.e. expansion or depletion of this population, 
following transplantation can be analyzed by direct measurement of hematopoietic stem cell numbers 
by flow cytometry. However given that the LKS immunopheotype becomes less reliable for 
hematopoietic stem cell identification after transplantation into irradiated recipients[58] direct 
assessment of functionality by transplantation into secondary recipients is necessary. Thus the ability 
to engraft in irradiated recipients is the most accurate depiction of hematopoietic stem cell 
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functionality, the cellular mechanism for which can be explained by in vitro proliferation and colony 
forming assays. 
The proliferative ability of a stem cell enriched population can be assessed in vitro by culture 
in liquid medium with minimal cytokine support, typically with stem cell factor (SCF) and 
thrombopoietin (TPO)[53]. Although maintenance of stem cell functionality (hematopoietic 
reconstitution of irradiated hosts) is lost during culture, this assay can provide insights into the 
mechanism by which an observed in vivo engraftment defect occurs. Single cell liquid culture of 
highly enriched hematopoietic stem cells can also be employed to provide more direct evidence of 
stem cell phenotype following gene targeting. Owing to the ease by which single cells can be isolated 
by FACS this assay has largely replaced the long-term culture initiating cell (LTC-IC) assay which 
relied on the propagation of cobblestone areas on irradiated bone marrow stroma over the course of 
four to five weeks. The ability of hematopoietic progenitor cells, the direct progeny of hematopoietic 
stem cells, to differentiate can be elucidated by their ability to form myeloid lineage colonies in 
methylcellulose which is known as the colony forming cell (CFC) assay. The ability of these 
hematopoietic progenitors to proliferate can be further assessed by serial CFC assays[59]. An 
increase in the number of cells in liquid culture in conjunction with maintained colony-forming ability in 
serial CFC assays can represent stem cell expansion.  Alternatively a proliferative defect and 
decreased number of colonies with serial CFC assays suggests a loss of self-renewal ability.  Taken 
together these in vitro assays can provide a cellular mechanism for an observed engraftment 
phenotype following molecular targeting. 
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1.3 MOLECULAR REGULATION OF HEMATOPOIETIC STEM CELLS 
 
 
1.3.1 Cell Cycle Regulation 
The observation that hematopoietic stem cells largely reside within G1/G0 phases of the cell cycle and 
cycle with slow kinetics[60] suggests that progression through the cell cycle is an important 
mechanism regulating hematopoietic stem cell function. Movement through G1 is governed by the 
phosphorylation of members of the retinoblastoma family of genes, including Rb, p107, and p130, by 
cyclin dependent kinases[61]. Loss of Rb alone has a limited cell intrinsic effect on hematopoietic 
stem cell function[62]; loss of all three retinoblastoma family members in mice, Rb, p107, and p130, 
leads to excessive proliferation within the hematopoietic stem cell compartment and eventually a 
myeloproliferative disease arising from hematopoietic progenitors[63]. Mice lacking D type cyclins 
lose hematopoietic stem cells during development which is associated with decreased hematopoietic 
progenitor proliferation during in vitro culture and increased percentage of cells in G1 in vivo [64]. 
Similarly cdk4/cdk6 double knockout mice die at late gestation with evidence of limited hematopoiesis 
owing to decreased proliferation of myeloid progenitors [65]. . This data indicates that proper 
regulation of the cell cycle in hematopoietic stem cells is necessary not only for their maintenance but 
also serves to limit possible malignant transformation. 
The cyclin dependent kinases are in turn inhibited by two families of cyclin-dependent kinase 
inhibitors, the CIP-KIP family and the INK4 family. The former is composed of p21, p27, and p57, 
while the latter is composed of p16, p15, p18 and p19[66]. The CIP/KIP family of cyclin dependent 
kinase inhibitors block progression into S-phase promoted by cdk2/cyclin E or cyclin A. Mice deficient 
in p21 show increased cycling within the hematopoietic stem cell compartment and as a result 
increased incidence of hematopoietic failure following treatment with the S-phase toxin 5-
fluorouracil[67]. Moreover serial transplantation of these cells into irradiated recipients, leads to 
exhaustion of their repopulating ability after 5 rounds of transplantation whereas wild-type cells 
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maintained fifty percent of their reconstituting ability[67]. In contrast to loss of p21, loss of p27 leads to 
expansion of hematopoietic progenitors without affecting hematopoietic stem cell number or self-
renewal[68]. Owing to this progenitor expansion p27 knock-out cells out-compete wild-type cells in 
competitive bone marrow transplantation[68]. Thus despite their overlapping roles in regulating cdk2 
these molecules have distinct roles in maintaining stem cell quiescence and restricting progenitor cell 
proliferation. 
The INK4 family of cyclin dependent kinase inhibitors restrict the activity of cyclin dependent 
kinases 4 and 6 and downstream phosphorylation of the retinoblastoma family of proteins. p18  
knock-out mice exhibit increased stem cell pools in the bone marrow as compared to wild-type mice 
and bone marrow from p18 knock-out  mice can out-compete freshly isolated wild-type bone marrow 
in competitive transplantation models[55]. Fetal hematopoietic stem cells, which can outperform 
hematopoietic stem cells from aged mice, express lower levels of p18 which can compensate for 
limited hematopoietic stem cell function in the absence of p21[57]. Thus while both p21 and p18 can 
increase the cycling of hematopoietic stem cells the outcome of these divisions favors self-renewal in 
the absence of p18 as opposed to loss of the stem cell function in the absence of p21. 
p16 has been shown to play a role in stem cell aging. Hematopoietic stem cells from aged 
mice express higher levels of p16 than young mice. Bone marrow cells from eight to twelve week old 
p16 knock-out mice are roughly equivalent to their wild-type counterparts in their ability to repopulate 
irradiated recipients. However  bone marrow cells in mice older than fifty-six weeks that lack p16 can 
outcompete aged match controls most likely due to an increased number of cycling hematopoietic 
stem cells as measured by BrdU uptake as well as decreased levels of apoptosis[69]. A similar 
phenotype was observed in neural precursor cells lacking p16[70]. These studies serve to 
underscore the necessity of proper regulation of the cell cycle within the hematopoietic stem cell 
compartment to maintain a reserve of these cells over the lifetime of the individual.  Moreover genes 
with overlapping functions at the molecular level may have distinct roles in the regulation of the 
functionality of hematopoietic stem cells. 
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1.3.2 Homeobox Proteins 
The mammalian homeobox family is composed of 39 proteins sharing a common helix-turn-helix 
DNA binding motif clustered in 4 groups named A through D[71]. Of these groups the 3’ end of 
homeobox clusters A and B have been shown to be uniquely over-expressed in both mouse[72] and 
human[73, 74] hematopoietic stem and progenitor cells. Expansion of hematopoietic stem cells with 
maintenance of their differentiation and hematopoietic reconstitution ability was achieved by retroviral 
transduction of HoxB4 into mouse[75] and human[76] bone marrow cells. This expansion was 
enhanced in a p21-null background[77], further validating p21’s role in suppression of stem cell self-
renewal. HoxB4 has proven to be unique in that overexpression of this molecule within the 
hematopoietic compartment can generate a cell intrinsic expansion of functional hematopoietic stem 
cells. 
The HoxA cluster of proteins has been implicated in leukemia development, particularly in the 
setting of Nup98-HoxA9 translocation[78] or overexpression of multiple homeobox proteins in 
leukemias harboring an MLL translocation[79, 80]. Overexpression of HoxA9 in hematopoietic 
progenitor populations ultimately leads to acute myeloid leukemia with a latency of up to ten 
months[81]. Prior to leukemogenesis HoxA9 induces hematopoietic stem cell expansion and 
leukemogenesis was not observed up to 8 months following transplantation of lymphoid restricted 
cells over-expressing HoxA9[82]. Transduction with HoxA10 led to disruption of both myelo- and 
lymphopoiesis and induction of an acute myeloid leukemia in mice with a latency similar to that 
observed for hematopoietic progenitor cells transduced with HoxA9[83]. Similar to their role in tissue 
patterning in the developing embryo, hematopoiesis requires cell-type specific expression of the 
HoxA cluster in that overexpression of HoxA9 and HoxA10 can lead to physiologic expansion of 
hematopoietic stem cells but their overexpression in hematopoietic progenitors can lead to 
leukemogenesis. 
 
 
16 
 
The HoxA cluster is in turn regulated by the mixed lineage leukemia (MLL) gene, a histone 
methyltransferase, in hematopoietic stem cells. Embryonic mice heterozygous for MLL have 
hematopoietic and skeletal defects associated with caudally shifted expression of HoxA7 and 
HoxC9[84]. Conditional deletion of MLL from adult hematopoietic cells has been shown to lead to 
loss of self-renewal in irradiated recipients most likely due to inappropriate cell cycle entry within the 
hematopoietic stem cell compartment[85, 86]. However a role for MLL under homeostatic conditions 
remains controversial[85, 86]. These defects following MLL deletion occur in the setting of down-
regulation of expression of the HoxA cluster within hematopoietic stem and progenitor cells[85] and 
MLL translocations lead to overexpression of HoxA genes[87]. The observation of the histone 
modifying enzyme MLL’s regulation of HoxA cluster expression underscores the potential role for 
epigenetic regulation of gene expression within hematopoietic stem cells. 
 
 
1.3.3 Developmental Regulators in Hematopoietic Stem Cells 
A role for a number of other molecules in hematopoietic stem cell function has been elucidated by 
conditional deletion or overexpression within this population as summarized in Figure 1-3. In general 
genetic perturbations that increase the rate of hematopoietic stem cell cycling due so at the expense 
of an increased number of symmetric divisions yielding two progenitor, i.e. more differentiated, 
daughter cells, and subsequent stem cell exhaustion. Hematopoietic stem cells lacking the gene 
Growth factor independent 1 (Gfi-1) show increased rates of BrdU uptake in vivo and failure to 
sustain long-term hematopoietic reconstitution in irradiated recipients[88]. Loss of the tumor 
suppressor PTEN (Phosphatase and tensin homolog) leads to a myeloproliferative disease and rapid 
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leukemia induction as well as increased hematopoietic stem cell cycling and loss of functionality[54, 
89]. Wnt signaling, via -catenin, can expand the hematopoietic stem cell pool likely through 
activation of both intracellular HoxB4 and expression of Notch at the cell surface[90]. Wnt signaling is 
particularly dependent on Notch to act as an inhibitor of differentiation indicating that an Wnt induced 
prolifeation would lead to stem cell exhaustion if not for its inhibition by Notch[91]. Hematopoietic 
stem cells lacking Bmi-1 only transiently contribute to hematopoiesis and have a decreased ability to 
self-renewal which can be compensated for by forced expression of p16 and p19[92]. Thus multiple 
unique genetic programs regulate hematopoietic stem cells, the coordination of which during 
hematopoiesis and maintenance of the stem cell pool, has not been fully addressed. 
 
 
 
 
1.4 DNA METHYLATION AND THE DNA METHYLTRANSFERASES 
 
 
1.4.1 The DNA Methyltransferase Family 
The data summarized in Figure 1-3 indicates that precise regulation of gene expression levels, both 
within hematopoietic stem cells and their progeny, is necessary for their maintenance and function. 
Given that epigenetic regulation of gene expression by DNA methylation has been shown to play a 
role in the differentiation and self-renewal of a number of pluripotent cell types[2-4] investigation of 
DNA methylation in hematopoietic stem cells is warranted. DNA methylation of CpG dinucleotides in 
mammals is initiated and maintained by a family of DNA methyltransferases diagrammed in Figure 1-
4. DNMT1 was the first cloned  
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All members of the DNA methyltransferase family have core catalytic motifs that are shared 
from bacteria through mammals[98]. DNA methylation proceeds through a covalent intermediate 
formed between a cysteine residue in the enzyme and the target cytosine base which is flipped out of 
the DNA backbone. This is followed by transfer of a methyl group to the C-5 position in cytosine from 
an adenosine methionine donor[99]. The N terminal domains of mammalian methyltransferases have 
not been fully characterized. Consistent with its role in methylating daughter strands during DNA 
replication,  two regions in the N-terminus of DNMT1 have been shown to be important for 
localization to the replication fork: a DNA replication foci targeting domain and a polybromo homology 
domain[98]. The N-terminus of DNMT1 also contains a cysteine rich ATRX domain important for 
DNA binding[98]. The proline-tryptophan-tryptophan-proline (PWWP) motif in DNMT3a and DNMT3b 
has been crystallized and shown to enhance binding to pericentric heterochromatin[100, 101]. 
Disruption of this domain blocks the ability of both DNMT3a and DNMT3b to methylate major satellite 
repeats within pericentric heterochromatin although the PWWP domain of DNMT3b shows a greater 
binding affinity for nucleosomal DNA than that of DNMT3a[101]. The enhanced chromatin DNA 
binding of DNMT3b as compared to DNMT3a may also be due to an I662N substitution in the active 
site loop of mammalian DNMT3b which lies in close proximity to the phosphate backbone of the 
target DNA sequence[102]. Consistent with the enhanced binding of DNMT3b to heterochromatin 
DNT3b also shows increased methyltransferase activity on reconstituted nucelosomal DNA as 
compared to DNMT3a[103]. The pleckstrin homology domain (PHD in Figure 1-4) has been shown to 
recruit histone deacetylases and therefore can allow DNMT3a and DNMT3b to act as transcriptional 
repressors in the absence of their DNA methyltansferase activity[104]. These differences in 
molecular enzymology may explain the unique activities of DNMT3a and DNMT3b in multiple cell 
types as discussed below. 
 
 
 
 
 
21 
 
 
1.4.2 DNA Methylation and Regulation of Gene Expression 
DNA methylation occurs at CpG dinucleotides which are present at only one-fifth of their expected 
frequency of one out of every sixteen dinucleotide pairs in the human genome [105]. Approximately 
one percent of all cytosines are methylated which corresponds with nearly seventy to eighty percent 
of all CpG dinucleotides[98, 106]. Methylation of a gene’s CpG island, a clustering of CpG 
dinucleotides in the promoter and 5’ region, is associated with transcriptional silencing via direct 
inhibition of transcription factor binding or recruitment of components of the chromatin modifying 
machinery[107]. However the majority of CpG islands are unmethylated, despite a high degree of 
methylation throughout the genome, even in genes that show a distinct tissue specific expression 
pattern and methylation of the CpG island is not a prerequisite for gene silencing[108]. Variations in 
DNA methylation have recently been proposed to occur most often at CpG shores, genome regions 
within 2.5 kilobases on either the 5’ or 3’ end of a CpG island. Comparing genome wide methylation 
differences between tissues or normal tissue and cancerous lesions from the same tissue[108], as 
well as embryonic and induced pluripotent stem cells[109], have shown that the majority of 
differentially methylated regions reside in these CpG shores. Moreover methylation within these CpG 
shore regions of genes is associated with gene expression rather than repression[108, 109]. 
How then does DNA methylation induce expression of a gene? A study of DNMT3a in neural 
precursor cells indicated an interplay between DNA methylation and histone modifications may 
generate a permissive chromatin state in the presence of DNA methylation. . Genes that were down 
regulated in DNMT3a knock-out cells generally were hypo-methylated in their respective CpG 
shores. This hypo-methylation was associated with increased H3K27 trimethylation, a repressive 
histone methylation mark. Methylation of the genomic DNA by DNMT3a and not the presence of 
DNMT3a itself, allowed for PcG2 dependent changes in histone methylation[110]. Genome wide 
microarray analysis of changes in methylation during hematopoietic development also demonstrates 
that a majority of lineage dependent changes in DNA methylation to occur in close proximity to, but 
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not overlapping, the identified CpG island of the gene[111]. This suggests a close interplay between 
DNA methylation and the histone code and that methylation carried out by the de novo 
methyltransferases may allow for gene specific regulation of expression. 
 
 
1.4.3 De Novo Methylation in Development and Cancer 
The roles of the DNA methyltransferases during development and tumorigenesis are summarized in 
Table 1-1. . DNMT3b is expressed early during embryogenesis in totipotent cells of the inner cell 
mass and epiblast while DNMT3a is expressed after E10.5[112]. This may correlate with the different 
phenotypes of the respective knock-out mice; DNMT3b knock-out mice die in utero around day 
E12.5 while DNMT3a knock-out mice die within four weeks after birth[9]. Loss of DNMT1 is also 
embryonic lethal and associated with global hypomethylation[113]. Loss of both DNMT3a and 
DNMT3b from embryonic stem cells leads to a loss of DNA methylation at both repetitive and distinct 
sites within the genome that can be restored by re-introduction of either  
 
Table 1-1. Summary of DNA Methyltransferase Family Members in Development and Cancer 
 Knockout Mouse Phenotype ES cell phenotype Cancer phenotype 
DNMT1 Death at E10.5 
Global Demethylation [113] 
Microsatellite instability 
[114] 
Mitotic defects in 
HCT116 cancer cells 
[115] 
DNMT3a Die four weeks after birth [9] Loss of methylation with 
DNMT3b deletion [9] 
Enhanced melanoma 
growth and metastasis 
[116] 
DNMT3b Death at E12.5 [9] Loss of methylation with 
DNMT3a deletion [9] 
Enhanced APC induced 
colon cancer growth 
[117] 
DNMT3L Hypogonadism, azoospermia 
in males [118] 
Heterozygous females infertile 
[119] 
Loss of methylation 
accelerated in female 
ES cells [120] 
Enhanced human 
embryonal carcinoma 
growth [121] 
 
Phenotypes indicated for embryonic stem (ES) cells and cancer are those observed following 
deletion of the DNMT in the indicated cell or cancer type.  
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DNMT3a or DNMT3b, but not DNMT1[2]. This data suggests that in embryonic stem cells 
methylation of certain loci is maintained by DNMT3a and DNMT3b apart from the  
maintenance methyltransferase activity of DNMT1 and assigns relatively unique roles for the de novo 
methyltransferases in this population of stem cells. 
Expression of DNMT3a and DNMT3b, but not DNMT1, was also shown to be necessary for 
the formation of teratomas following injection of embryonic stem cells into nude mice[2]. This data 
correlates with evidence that cancer cells can maintain hyper-methylation of the genome in the 
absence of DNMT1[122]. However depletion of DNMT3b but not DNMT3a from human cancer cells 
resulted in apoptosis and re-expression of hyper-methylated genes due to their demethylation[123]. 
Double knockdown of DNMT1 and DNMT3b abrogated almost all methyltransferase activity in 
human colon cancer cells allowing for enhanced de-methylation of hyper-methylated genomic 
sequences[124]. DNMT3b has also been shown to play a role in tumor initiation in an Adenomatous 
Polyposis Coli (APCmin/+ ) model of intestinal neoplasia. Inactivation of DNMT3b led to a decrease in 
macroadenoma formation[117] while overexpression of DNMT3b but not DNMT3a increased the 
number and size of adenomas in APCmin/+ mice[125]. Aberrant splicing of DNMT3b may also 
contribute to the hypermethylator phenotype in cancer cells[126, 127]. Taken together with the data 
from embryonic stem cells the changes in the expression of the de novo methyltransferases 
DNMT3a and DNMT3b can alter DNA methylation levels independent of DNMT1 and these two 
molecules have unique roles within different cell types. 
 
 
1.4.4. ICF Syndrome 
Somatic mutations in DNMT3b in humans are associated with an autosomal recessive syndrome 
characterized by  immunodeficiency, centromeric region instability, and facial (ICF) 
abnormalities[128]. These mutations have been shown to decrease the methyltransferase activity of 
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DNMT3b by ten to fifty fold but not completely abrogate its activity[129] consistent with the embryonic 
lethality of DNMT3b knockout mice[9]. The centromeric region instability is generally thought to be 
caused by hypo-methylation of the pericentromeric regions of chromosomes 1, 9 and 16[130]. 
However only a small decrease in overall genomic DNA methylation levels have been observed[130]. 
Wide variability is seen in the range of symptoms perhaps due to differences in the residual level of 
methyltransferase activity as well as the fact the not all patients showing the characteristic features of 
ICF syndrome have demonstrable mutations in DNMT3b[131-133]. ICF syndrome can be corrected 
by bone marrow transplantation[134] indicating a cell intrinsic defect in hematopoietic cells in the 
absence of DNMT3b. ICF syndrome suggests a role for DNA methylation in hematopoiesis as well 
as a unique role for DNMT3b within this system. 
 
 
1.4.5 DNA Methylation and Hematopoiesis 
While the maintenance methyltransferase DNMT1 is expressed in all hematopoietic lineages[8] 
DNMT3a and DNMT3b have been shown to be uniquely expressed in hematopoietic stem cells of 
mice[8] while other studies have shown increased expression of DNMT3b alone in hematopoietic 
stem cells of mice[7] and humans[135]. Overexpression of DNMT1, DNMT3a, and DNMT3b has 
been observed in AML and CML cell lines and primary cells[135]. In addition demethylating agents, 
such as 5-aza-deoxycytidine, have proven to be effective in myelodysplatic syndromes and certain 
leukemias[136]. Taken together with the expression data of the DNA methyltransferase family, 
increased DNA methylation appears to be associated with leukemogenesis. Indeed we have shown 
T cell leukemogenesis in a p18-null background is commonly associated with methylation of the 
promoter of p15 and/or p16 [137]. These results underscore the potential role of DNA methylation 
and in particular the de novo methyltransferases, due to their unique expression in the most 
immature cells in the bone marrow, in regulating hematopoietic stem cell function. 
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A role for DNMT1 in hematopoiesis has not been clearly defined. Broske et al demonstrated 
that loss of DNMT1 by Cre mediated recombination led to bone marrow failure and death of the 
animals by three weeks[6]. Mice with one hypomorphic DNMT1 allele demonstrated an increased 
frequency of long-term hematopoietic stem cells and decreased frequency of highly proliferative 
progenitors in the bone marrow under homeostatic conditions[6]. When transplanted into irradiated 
recipients hematopoietic stem cells containing the hypomorphic DNMT1 allele failed to recapitulate 
hematopoiesis following serial transplantation indicating a self-renewal defect in hematopoietic stem 
cells in the absence of DNMT1[6]. Also while DNMT1 hypomorphic mice had normal myeloid cell 
frequencies in the bone marrow and blood, lymphoid progenitor and differentiated cells in these mice 
were nearly absent[6]. In contrast Trowbridge et al did not observe any changes in hematopoiesis 
under homeostatic conditions with DNMT1 deletion but did observe engraftment and self-renewal 
defects when these cells were transplanted into irradiated recipients[5]. Unlike Broske et al this 
engraftment defect was found to occur primarily because inadequate generation of the myeloid 
lineage[5]. While Broske et al did show changes in DNA methylation after loss of DNMT1 at two 
myeloid restricted genes neither work proposed changes in gene expression or associated DNA 
methylation to explain the observed self-renewal defect[5, 6]. A similar study with DNMT3a and 
DNMT3b failed to identify any molecular targets underlying hematopoietic stem cell dysfunction in the 
absence of both de novo methyltransferases[8]. An assessment of methylation changes near and 
within CpG islands has identified a number of genes, including DNMT3b, that may be regulated by 
DNA methylation during hematopoiesis[111], however the DNA methyltransferases responsible for 
these changes have not been addressed.   
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1.5 GOALS OF DISSERTATION RESEARCH AND SUMMARY OF FINDINGS 
 
 
Hematopoietic stem cells reside in a specialized niche within the bone marrow of adults and can be 
isolated by flow cytometry. These cells are largely defined functionally by their ability to engraft in 
irradiated recipients. While a number of different genetic programs have been shown to regulate 
hematopoietic stem cell function, the coordination of expression of these programs during 
hematopoietic development has yet to be fully elucidated. DNA methylation is an epigenetic means 
of regulation of gene expression that is maintained and carried out by a family of DNA 
methyltransferases. A role for DNA methylation in the hematopoietic system has been suggested by 
studies of DNMT1 within these cells and observations of the changes in DNA methylation during 
hematopoietic development. Of the DNA methyltransferse family the de novo methyltransferases 
DNMT3a and DNMT3b appear to play roles in other stem cell types as well as in cancer intiation and 
maintenance. In particular, DNMT3b is uniquely expressed with hematopoietic stem cells and 
inherited mutations in DNMT3b lead to a syndrome characterized by immunodeficiency. Therefore 
this study proposes to elucidate the role of DNMT3b in hematopoietic stem cells. 
The findings presented in Chapter 2 confirm the overexpression of DNMT3b in hematopoietic 
stem cells of mice. Targeted knockdown of DNMT3b by short, hairpin RNA limits hematopoietic 
engraftment of bone marrow cells in both the blood and bone marrow of recipient mice and is 
associated with a decreased proliferative capacity in vitro. Specific recombination of floxed DNMT3b 
alleles indicates a cell intrinsic effect of DNMT3b on hematopoietic stem cell self-renewal and 
enhanced apoptosis in the absence of DNMT3b in vivo. This effect was stem cell specific, as single 
cell culture or transplantation of hematopoietic stem cells, demonstrated a defect in proliferation or 
engraftment, respectively. Moreover the function of DNMT3b in hematopoietic cells requires its 
methyltransferase activity and loss of DNMT3b is associated with down-regulation of MLL expression 
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in stem cell enriched bone marrow cells concurrent with demethylation of this locus. Taken together 
this data indicates a cell intrinsic role for DNMT3b in regulating hematopoietic stem cell function via 
maintenance of MLL expression. 
All of the experiments in this thesis were performed by Matthew Boyer, with the assistance of 
Hui Yu and Richard XuFeng.  
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2.0 DNMT3B’S ROLE IN HEMATOPOIETIC STEM CELLS 
 
 
2.1 INTRODUCTION 
 
 
Hematopoiesis proceeds from a bone marrow resident population of hematopoietic stem cells which 
must balance self-renewal versus differentiation in order to maintain a stem cell pool that can 
produce all lineages within the blood over the lifetime of an organism. Distinct molecular programs in 
hematopoietic stem cells are the key to maintenance of hematopoiesis under homeostatic conditions 
and their dysregulation can lead to a number of pathological states, including leukemia. However the 
mechanism by which these molecular programs are regulated remain largely undefined.  
 Epigenetic regulation of gene expression by DNA methylation has been shown to play a role 
in a number of pluripotent cell types[3, 9], including hematopoietic stem cells[111]. DNA methylation 
is initiated and maintained in mammals by a family of DNA methyltransferases[98]. Of these the de 
novo mehyltransferase DNMT3b is uniquely overexpressed in murine hematopoietic stem cells as 
compared to DNMT3a[138]. Aging murine hematopoietic stem cells exhibit epigenetic dysregulation 
including down-regulation of DNMT3b which correlates with a decrease in functionality[139]. Bone 
marrow transplantation in humans was shown to correct the immunodeficiency in a small cohort of 
patients with mutations in the DNMT3b gene[140], suggesting a hematopoietic stem cell intrinsic 
defect in these patients. Using hematopoietic stem cells from mice with floxed DNMT3a and/or 
DNMT3b, it was recently shown that loss of both methyltransferases blocked engraftment in 
irradiated recipients[8]. However the cellular and molecular mechanisms underlying this defect were 
not vigorously addressed[8]. Taken together, this data strongly indicates a role for DNMT3b in 
regulating hematopoietic stem cell function.  
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By knock-down of DNMT3b with a retrovirally delivered shRNA or Cre mediated 
recombination of floxed DNMT3b alleles work presented in this thesis demonstrates a critical role for 
DNMT3b in hematopoiesis in mice. Loss of DNMT3b leads to limited reconstitution of hematopoiesis 
in irradiated recipients associated with a proliferative defect in vitro and a failure of hematopoietic 
stem cell self-renewal in vivo. Targeted deletion of DNMT3b in hematopoietic stem cells leads to 
decreased engraftment following transplantation and decreased proliferation in vitro. DNMT3b 
function in hematopoietic cells requires the methyltransferase activity of the enzyme and the defects 
in hematopoiesis are associated with loss of DNA methylation and decreased expression of MLL. 
Therefore DNMT3b is necessary for maintenance of the proliferative ability and engraftment capacity 
of hematopoietic cells and hematopoiesis is dependent upon appropriate DNA methylation.  
 
 
 
 
2.2 MATERIALS AND METHODS 
 
 
2.2.1 Mice 
DNMT3blox/lox mice in a C57BL/6 background were a kind gift of En Li. Wild-type C57Bl/6 and B6.Cg-
Tg(CAG-cre/Esr1)5Amc/J (ER-Cre) mice were purchased from the Jackson Laboratory. ER-Cre 
mice were crossed to our DNMT3blox/lox mice which were bred in-house. Excision of floxed DNMT3b 
alleles in DNMT3blox/lox ER-Cre mice was accomplished by oral administration of 5 mg tamoxifen 
(Sigma) in 0.1 mL of peanut oil daily for 5 days. In vitro excision of floxed DNMT3b alleles was 
accomplished by treatement with 1 M 4-hydroxytamoxifen. Mice were genotyped by PCR primers 
flanking the either loxP insertion site. All mice were handled in accordance to institutional guidelines 
for animal care. 
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2.2.2 Retroviral Vectors  
A U6 promoter construct was cloned from the lentiviral vector pLL3.7, a kind gift from Tyler Jacks, 
into MSCV-pgk-GFP, a kind gift from Guy Sauvageau, to generate MSCV-U6. A 19 bp shRNA with 
an 8 bp loop targeting DNMT3b was cloned into the HpaI and XhoI sites of MSCV-U6. Replication 
incompetent retroviral particles were generated by transient transfection of 5 micrograms of MSCV-
shRNA or MSCV-U6 along with 2.5 micrograms of the packaging plasmid pKat and 2.5 micrograms 
of the envelope plasmid pVSV-g into 293T cells with Lipofectamine 2000 (Invitrogen) per the 
manufacturer’s instructions. Forty-eight hours after transfection retrovirus containing supernatants 
were collected, spun at 1300 rpm for 10 minutes, passed through a 0.45 micron filter and used for 
transduction. 
 
 
2.2.3 Retroviral Transduction 
Lineage- or c-kit+ bone marrow cells from 8-12 week old wild-type C57Bl/6 or DNMT3blox/lox ER-Cre 
mice were flushed from the long bones and enriched with the MACS Streptavidin or MACS CD117 
Enrichment Kit and Separation columns (Miltenyi Biotec) per the manufacturer’s instructions. The 
cells were pre-stimulated overnight with 50 ng/ml SCF, 10 ng/ml TPO and 10 ng/ml Flt-3L (all from 
Peprotech) in X-Vivo-15 (Lonza) at 37 oC, 5% CO2. 1 to 5 x 105 cells were plated per well in a 24 well 
plate pre-coated with retronectin (Takara) for four hours and spun at 1700 rpm for 30 minutes with 
80% retroviral supernatant in X-Vivo 15 with cytokines. Following overnight culture at 32 oC, 5% Co2 
the cells were harvested and cultured in fresh media for 48 hours prior to cell sorting or use in vitro or 
in vivo assays. 
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2.2.4 Bone Marrow Cell and Hematopoietic Stem Cell Transplantation.  
Sixteen hours before transplantation, 6 to 8-week-old recipient C57Bl/6 mice were lethally irradiated 
to 9.5 Gy at 82 cGy/min on a 137Cs  radiator. The indicated cell populations in each experiment were 
sorted and injected into the tail veins of recipients. Recipient mice were supplied with sterile food and 
acidified water. Multilineage engraftment in peripheral blood was monitored monthly for 3 months by 
flow cytometry and bone marrow engraftment measured after sacrificing the animal at 3 months. 
Secondary transplantation was performed by collecting donor cells from primary recipients and 
injecting, via the tail vein, into irradiated recipients. 
 
 
2.2.5 Flow Cytometry 
Cultured and freshly harvested bone marrow cells were stained with a Lineage cocktail containing 
equal amounts of anti-CD3, anti-CD4, anti-CD8, anti-CD11b, anti-B220, anti-Ter119, and anti-Gr-1 
conjugated to PE-Cy7, anti-ckit conjugated to PE or APC, anti-Sca-1 PE-Cy5.5, anti-CD34 FITC, 
anti-FcR Pacific Blue, and anti Il-7R APC as appropriate and sorted by MoFlo or analyzed on a 
Cyan ADP flow cytometer. 
 
 
2.2.6 Liquid Culture 
1,000 GFP+ cells were sorted forty eight hours after culture into four  wells of a 96-well plate per 
group containing X-Vivo 15 plus 50 ng/ml SCF, 10 ng/ml TPO and 10 ng/ml Flt-3L. Cells were 
cultured for 14 days during which time aliquots of each well were taken and counted. 
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2.2.7 Colony Forming Cell (CFC) Assay 
GFP+ cells were sorted forty-eight hours after transduction, resuspended in semisolid methylcellulose 
medium M3434 (StemCell Technologies) and plated in triplicate in 24-well plates at 1,000 cells/well. 
The cells were cultured at 37 °C, 5% CO2 and colonies counted after 7–11 days in culture. For the 
secondary CFC assay primary colonies were harvested by triplicate washes with 1X PBS, spun 
down, and counted. 5,000 cells were then re-plated in fresh M3434 media and cultured as above for 
another 7-11 days and the colonies counted. 
 
 
2.2.8 Quantitative Real-Time RT-PCR 
Five thousand hematopoietic cells from 6- to 8-week-old C57Bl/6 mice were directly sorted into cell 
lysis buffer and the RNA was extracted using Absolute RNA extraction kits (STRATAGENE) 
according to the manufacturer’s instructions. cDNA was synthesized using SuperScript II (Invitrogen) 
according to the manufacturer’s instructions and real-time RT-PCR was performed using 
DynamoSYBR green qPCR kit (Finnzymes) on a PTC-200 thermo cycler (MJ Research) according 
to the manufacturer’s instructions. 
 
 
2.2.9 Annexin V Staining 
1 x105 to 5 x106 bone marrow cells were first stained with antibodies for hematopoietic stem cells as 
described in 2.2.5 and then stained with Annexin V PE and 7-AAD using the Annexin V:PE Apoptosis 
Detection Kit (BD Pharmingen) per the manufacturer’s instructions. Apoptotic cells that are either 
Annexin V positive or Annexin V/7-AAD double positive were analyzed on a Cyan ADP flow 
cytometer. 
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2.2.10 BrdU Staining 
Mice were given an intraperitoneal injection of 0.5 mg of BrdU in PBS sixteen hours prior to 
sacrificing and collection of the bone marrow. Cells were first stained with antibodies for 
hematopoietic stem cells as described in 2.2.5 and then fixed, permeabilized and stained with anti-
BrdU FITC using the BrdU Flow kit from BD Pharmingen according to the manufacturer’s instructions 
and analyzed on a Cyan ADP flow cytometer. 
 
 
2.2.11 Bisulfite Sequencing 
The DNA from 1x106 whole bone marrow cells was collected by the DNEasy Extraction Kit (Qiagen) 
per the manufacturer’s instructions and re-suspended in 200 microliters of TE. Forty microliters was 
subsequently bisulfite treated using the EpiTect Bisulfite Kit (Qiagen) per the manufacturer’s 
instructions. One microliter of the bisulfite treated DNA was then amplified by nested PCR, the 
product isolated by gel electrophoresis, and collected by Wizard SV Gel and PCR Purification Kit 
(Promega) per the manufacturer’s instructions. The amplified fragment was then cloned with the 
pGEM-T Easy Vector System (Promega) per the manufacturer’s instructions and sequenced.  
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2.3 RESULTS 
 
 
2.3.1 DNMT3b is Uniquely Expressed in a Highly Enriched Hematopoietic Stem Cell Population 
In order to confirm previous studies showing up-regulation of DNMT3b in hematopoietic stem cells[7, 
141] stem, progenitor and mature cell populations were isolated from the bone marrow of C57Bl/6 
mice by flow cytometry and the relative expression of DNMT1, DNMT3a, and DNMT3b measured in 
each by quantitative real-time RT-PCR. In long-term hematopoietic stem cells (CD34-LKS) the 
expression of DNMT3b mRNA is 25.1 and 12.8 times higher than that of DNMT1 and DNMT3a, 
respectively, and approximately 4.5-fold higher than the expression of DNMT3b mRNA in any 
progenitor or mature hematopoietic population (Figure 2-1). This suggests a specific role for DNMT3b 
in hematopoietic stem cells as compared to more differentiated cell types as well as a specific 
function of DNMT3b as compared to other members of the DNA methyltransferase family within 
these cells. 
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2.3.2 DNMT3b Knockdown Limits Hematopoietic Reconstitution in Competitive Bone Marrow 
Transplantation 
In order to assess the role of DNMT3b in hematopoietic stem cells a murine stem cell virus (MSCV) 
harboring a short, hairpin RNA (shRNA) under the control of a U6 promoter with GFP as a marker of 
transduced cells was generated (Figure 2-2a). Transduction of stem cell enriched Lineage- (Lin-) 
bone marrow cells with the DNMT3b shRNA produced an approximately 93% reduction in DNMT3b 
expression at the RNA level by quantitative real-time, RT-PCR (Figure 2-2b) and significant loss of 
DNMT3b protein expression by Western blot when DNMT3b shRNA was transduced into the murine 
hematopoietic progenitor cell line 32D (Figure 2-2c). Although a significant decrease in DNMT3a was 
observed at the RNA level (Figure 2-2b) a similar decrease was not observed at the protein level 
(Figure 2-2c) suggesting the relative specificity of the transduced shRNA for DNMT3b. 
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To assess hematopoietic function following knockdown of DNMT3b, 1x105 retrovirally 
transduced Lineage- bone marrow cells sorted for GFP expression were transplanted along with 
1x105 freshly isolated whole bone marrow cells as competitors into 9.5 Gray irradiated recipients as 
outlined in Figure 2-3a. Bone marrow cells transduced with DNMT3b shRNA showed significantly 
limited engraftment ability in the peripheral blood of irradiated recipients at two (42.0 vs. 7.1) and 
three (61.4 vs. 2.83) months post-transplantation as compared to vector transduced cells (Figure 2-
3b). When compared to the engraftment in mice receiving vector transduced cells at one month post-
transplantation shRNA transduced bone marrow cells had a 3.2-times increased contribution to the 
myeloid (CD11b+) compartment which decreased to 0.07-times by three months post-transplantation 
(Figure 2-3c). shRNA and vector transduced cells showed approximately equivalent engraftment 
within CD3+ T cells and an increase in B220+ cells over the course of the transplantation (Figure 2-
3c) indicating the overall defect in engraftment is largely due to limited long-term myelopoiesis from 
cells in which DNMT3b has been knocked down. 
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Three months after transplantation engraftment within the bone marrow of the recipient mice 
was determined by flow cytometry. shRNA transduced bone marrow cells contributed to only 1.5% of 
the transplanted cells in the bone marrow as compared to vector transduced cells which constituted 
66.7% of transplanted cells (Figure 2-4a). While there was a similar percent of engraftment within the 
stem and progenitor enriched Lineage- and LKS populations a significant decrease in engraftment 
within the LKS- progenitor population was seen as a percentage of total engraftment (0.6 vs 0.03%, 
Figure 2-4b). However there was a significant decrease in the absolute number of all three stem and 
progenitor populations assessed (Figure 2-4c). Taken together with the peripheral blood engraftment 
the absolute lack of stem and progenitor cells is suggestive of a proliferative defect in hematopoietic 
stem cells in the absence of DNMT3b. Moreover given that the myeloid compartment is the most 
accurate depiction of the hematopoietic stem cell activity in the peripheral blood and the lack of 
engraftment within this compartment following DNMT3b knock-down as compared to vector control 
cells, DNMT3b may have a direct effect on hematopoietic stem cells themselves. 
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Figure 2-4. Limited Bone Marrow Engraftment of DNMT3b shRNA Transduced Bone Marrow 
Cells 
(a) Total bone marrow engraftment as a percentage of competitor and donor engraftment of recipient 
mice (n=5 mice per group, * = p < 0.05). (b) Percent engraftment within the donor derived cells in the 
bone marrow of recipient mice. Bone marrow cells were first gated on CD45.1 expression and then 
the percentage of cells within the indicated populations was determined by flow cytometry. Lin-, 
Lineage -; LKS- Lineage-ckit+Sca-1-;  LKS, Lineage-c-kit+Sca-1+. A significant decrease in the LKS- 
progenitor population is seen (n=5 mice per group, * = p < 0.05) (c) Absolute engraftment was 
calculated per femur by counting the recovered cells and then multiplying by the percent engraftment 
in (a) and the percent engraftment in the indicated lineages as described in (b). All three progenitor 
and stem cell enriched populations showed significant decreases in shRNA transduced cell recipient 
mice (n=5 mice per group, * = p < 0.05). 
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2.3.3 DNMT3b Knockdown Limits Hematopoietic Progenitor Proliferation In Vitro 
To address the cellular mechanism underlying the observed engraftment defect in vivo the stem cell 
enriched Lineage- population of bone marrow cells was cultured in vitro with limited cytokine support. 
Over the course of the two weeks in culture vector transduced cells increased almost 6-fold whereas 
the DNMT3b shRNA transduced cells failed to proliferate (Figure 2-5a, b). This failure to proliferate 
was associated with loss of the more immature Lineage-Sca-1+ population (Figure 2-6a) and an 
increase in apoptotic cells within this population as determined by Annexin V staining (Figure 2-6b) 
after fourteen days of culture. This data indicates the observed engraftment defect in vivo was likely a 
result of decreased proliferation concomitant with increased apoptosis in shRNA transduced 
hematopoietic cells. 
When plated in methylcellulose media immediately after sorting for GFP expression, 
DNMT3b shRNA transduced Lineage- bone marrow cells generated more colonies (Figure 2-7a) 
similar to the relatively increased myeloid engraftment at one month following transplantation (Figure 
2-3c). When five thousand of these cells were re-plated in fresh media, however, DNMT3b shRNA 
transduced cells lost almost all of their colony-forming ability (Figure 2-7b). This serial colony-forming 
ability has been employed as an indicator of the function of highly proliferative progenitors[142] again 
suggesting a proliferative defect in hematopoietic cells in the absence of DNMT3b. 
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2.3.4 Specific DNMT3b Deletion Reduces Hematopoietic Cell Numbers Under Homeostatic 
Conditions 
To control for any potential off-target effects of the DNMT3b shRNA employed above, mice harboring 
floxed DNMT3b alleles along with Cre under the control of an estrogen responsive promoter were 
bred. Treatment of these mice with tamoxifen allows for efficient deletion of DNMT3b (Figure 2-8a). 
To test the role of DNMT3b under homeostatic conditions DNMT3blox/lox ER-Cre+ mice were treated 
with tamoxifen (DNMT3b) and blood counts determined for three months (Figure 2-8b). Tamoxifen 
treated DNMT3blox/lox ER-Cre- (DNMT3blox/lox) mice were used as controls. Conditional deletion of 
DNMT3b did not affect the hemoglobin concentration in the blood of DNMT3b mice as compared 
to controls (Figure 2-8c) but did significantly decrease the platelet concentration (Figure 2-8d) at 3 
months after tamoxifen treatment. Loss of DNMT3b also lead to an increased number of white blood 
cells in the blood, although not significantly (Figure 2-8e). Three months after tamoxifen treatment the 
mice were sacrificed and the bone marrow, spleen and thymus analyzed. There was a significant 
decrease in the cellularity of the bone marrow, spleen and thymus of DNMT3b mice as compared 
to controls (Figure 2-8f). Similar to the transplant experiments with cells transduced with DNMT3b 
shRNA, although there was a similar percentage of progenitor and stem populations in the bone 
marrow (Figure 2-8g), the absolute number of both populations was significantly decreased (Figure 
2-8h) in DNMT3bmice as compared to controls. 
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Figure 2-8. DNMT3b Deletion Reduces Hematopoietic Cell Numbers Under Homeostatic 
Conditions 
(a) Efficient recombination of the floxed DNMT3b allele in bone marrow cells following tamoxifen 
treatments. Lox, floxed allele; recombined allele. (b) Diagram of tamoxifen treatment and analysis 
of peripheral blood and bone marrow. Hemoglobin (c), platelet (d), and white blood cell (e) counts in 
the peripheral blood of DNMT3blox/lox and DNMT3bmice (n=10 mice per group, * = p < 0.05). (f) 
Cellularity of one femur (BM), spleen, and thymus of DNMT3blox/lox and DNMT3bmice. There is a 
significant decrease in the cellularity of each hematopoietic organ in DNMT3bmice as compared to 
controls (n=10 mice per group, * = p < 0.05). (g) Percentage of progenitor and stem cell enriched 
LKS- and LKS cells within the bone marrow of DNMT3blox/lox and DNMT3bmice. (h) Absolute 
number of progenitor and stem cell enriched LKS- and LKS cells within one femur from DNMT3blox/lox 
and DNMT3bmice. Values were calculated by multiplying the total cell number in (f) by the 
percentage of each cell type in (g). There is a significant decrease in the absolute numbers of both 
hematopoietic progenitor and stem cell populations (* = p < 0.05). 
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This decrease in the absolute number of hematopoietic stem cells in the bone marrow of 
DNMT3b mice was associated with an increase in the apoptotic fraction within LKS cells (37.9% 
vs. 17.0%) by Annexin  V and 7-AAD staining as compared to DNMT3blox/lox controls (Figure 2-9a). 
LKS cells from DNMT3blox/lox and DNMT3b mice exhibited similar uptake of BrdU sixteen hours 
after a single intraperitoneal injection indicating equivalent rates of hematopoietic stem cell cycling 
within these two groups (Figure 2-9b). This data provides evidence that loss of hematopoietic stem 
cell numbers following DNMT3b excision is likely due to an increased rate of apoptosis as observed 
in vitro (Figure 2-6b) rather than changes in the cell cycle.  
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Figure 2-9. Increased Apoptosis in Hematopoietic Stem Cells in DNMT3b Mice 
(a) Apoptosis within the hematopoietic stem cell enriched LKS population of bone marrow cells as 
measured by annexin V and 7-AAD staining. Percentages in the scatter plot indicate the percentage 
of events within that region. (b) Cell cycle analysis of the hematopoietic stem cell enriched LKS 
population of bone marrow cells as measured by flow cytomtetry analysis of BrdU uptake. 
Percentages in the scatter plot indicate the percentage of events within that region. 
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2.3.5 DNMT3b Limits Hematopoietic Stem Cell Self-Renewal Via a Cell Intrinsic Mechanism 
In order to determine a cell intrinsic and specific role for DNMT3b in hematopoietic cells, as 
compared to cells of the hematopoietic niche, hematopoietic cells of irradiated wild-type mice were 
reconstituted with bone marrow from DNMT3blox/lox ER-Cre mice (Figure 2-10a). After allowing for 
stable engraftment for three months, donor DNMT3blox/lox ER-Cre cells comprised more than ninety-
seven percent of the myeloid (CD11b+) cells in the blood (Figure 2-10b). Half of the mice were then 
treated with tamoxifen and the engraftment in the peripheral blood monitored for another three 
months. Deletion of DNMT3b by Cre mediated recombination led to a significant decrease in 
peripheral blood engraftment within the myeloid compartment at two (98.7% vs 35.2%) and three 
(99.1% vs 28.1%) months post Cre induction (Figure 2-10b).  
This decrease in contribution to the myeloid compartment of the blood was paralleled by an 
approximately sixty percent decrease in the percentage of DNMT3b cells in the bone marrow and 
approximately thirty percent decrease in SLAM+ (CD150+CD48-) hematopoietic stem cells as 
compared to DNMT3blox/lox controls (Figure 2-11a). Within the donor cells in the bone marrow there 
was a slight percentage increase in CD34-LKS defined long-term hematopoietic stem cells, similar to 
the relative preservation of SLAM+ hematopoietic stem cells as compared to overall engraftment 
(Figure 2-11b). As a percentage of transplanted cells a decrease in common myeloid and 
granulocyte monocyte progenitors was observed similar to the more profound effect on progenitor 
(LKS-) engraftment seen with knockdown of DNMT3b with a retrovirally delivered shRNA (Figure 2-
4b). Taken together this data indicates impaired hematopoiesis in the absence of DNMT3b due to 
cell intrinsic defect. 
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Given that the LKS phenotype becomes less reliable for stem cell identification following 
transplantation[58] a secondary transplant was employed to test the self-renewal of hematopoietic 
stem cells in the absence of DNMT3b. Prior to transplantation, analysis of the recombination of 
DNMT3b indicated efficient deletion in DNMT3b mice (Figure 2-12a). Secondary recipient mice 
transplanted with one million DNMT3b bone marrow cells had an average engraftment within the 
blood of four percent at one month post-transplantation while DNMT3blox/lox cells constituted ninety-
one percent of peripheral blood cells (Figure 2-12b). This engraftment defect was not due to loss of a 
particular cell type as DNMT3blox/lox and DNMT3b had equivalent engraftment in all three lineages 
in the blood (Figure 2-12c). Similar to the engraftment within the peripheral blood, DNMT3blox/lox cells 
constituted nearly sixty percent of the bone marrow whereas engraftment in DNMT3b recipient 
mice was less than three percent (Figure 2-12d). This difference in engraftment in secondary 
recipients correlated with a re-emergence of the DNMT3b lox allele in the transplanted DNMT3b 
bone marrow cells following one month of engraftment (Figure 2-12e). This suggests that the 
observed engraftment, even at a low level, was at least partly due to residual cells that retained at 
least one DNMT3b allele after tamoxifen treatment and that these cells can out-compete cells in 
which both alleles of DNMT3b are deleted. Nevertheless this data indicates a self-renewal defect in 
hematopoietic stem cells following DNMT3b deletion and confirms a cell intrinsic defect in 
hematopoietic stem cell function observed following DNMT3b deletion. 
.  
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Figure 2-12. DNMT3b Deletion Limits Hematopoietic Stem Cell Self-Renewal 
(a) Recombination of the floxed DNMT3b allele in tamoxifen treated primary recipients. The DNMT3b 
genotype of three individual mice tamoxifen treated mice as well as one control is shown. (b) 
Peripheral blood engraftment in secondary recipients transplanted with either 1x106 DNMT3blox/lox or 
DNMT3b bone marrow cells. A significant decrease in total engrafted cells was observed at one 
month post-transplantation (n=10 mice per group, * = p <0.05). (c) Engraftment within B cell (B220), 
myeloid (CD11b), and T cell (CD3) lineages within the blood of secondary recipients transplanted 
with DNMT3blox/lox or DNMT3b bone marrow cells. (d) Total percent engraftment with the bone 
marrow of secondary recipients transplanted with DNMT3blox/lox or DNMT3b bone marrow cells. A 
significant decrease in engraftment of DNMT3b cells (n=10 mice per group, * = p <0.05) was 
observed. (e) Genotype of donor derived bone marrow cells in secondary recipients. The DNMT3b 
genotype of three individual DNMT3b recipients as well as one control is shown. An increase in the 
lox allele is observed in DNMT3b secondary recipients as compared to primary recipients. 
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2.3.6 DNMT3b Maintains the Functionality and Proliferative Capacity of Hematopoietic Stem Cells 
In order to test the role of DNMT3b in hematopoietic stem cells more directly five thousand         
CD34-LKS long-term hematopoietic stem cells were sorted from DNMT3blox/lox ER-Cre mice 
immediately after tamoxifen treatment and transplanted along with 5x105 whole bone marrow 
competitor cells into 9.5 Gray irradiated recipients (Figure 2-13a,b). Recombination of the floxed 
DNMT3b allele after tamoxifen treatment was confirmed by PCR (Figure 2-13c). At two months post-
transplantation DNMT3b cells only contributed to 56.8% of the engrafted cells in the peripheral 
blood while DNMT3b lox/lox cells made up 85.3% of engrafted cells (Figure 2-13d). This defect in 
engraftment at two months correlated with a decrease in the percentage of DNMT3b derived 
myeloid cells within the peripheral blood (Figure 2-13e) similar to the results seen following targeting 
of DNMT3b with a retrovirally delivered shRNA (Figure 2-3c). 
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Figure 2-13. DNMT3b is Required for Long-Term Hematopoietic Stem Cell Engraftment In Vivo 
(a) Diagram of the long-term hematopoietic stem cell transplantation. 5,000 long-term hematopoietic 
stem cells were sorted from DNMT3blox/lox ER-Cre- or DNMT3blox/lox ER-Cre+ mice following tamoxifen 
treatment and transplanted along with 5x105 whole bone marrow cells from wild-type mice into 9.5 
Gray irradiated recipients. (b) Flow cytometry strategy for isolation of long-term hematopoietic stem 
cells. (c) PCR confirmation of deletion of floxed DNMT3b alleles within the DNMT3b group. (d) 
Peripheral blood engraftment of donor-derived cells. DNMT3b cells had a significantly lower 
engraftment at 2 months post transplantation (n= 5 mice per group, * = p < 0.05). (e) Contribution to 
myeloid (CD11b), B cell (B220), and T cell (CD3) populations within the blood at one and two months 
post transplantation. The decrease in overall engraftment in DNMT3b recipient mice shown in (d) is 
paralleled by a decrease in myeloid engraftment as compared to DNMT3blox/lox recipients. 
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To further confirm a defect following DNMT3b loss at the hematopoietic stem cell level single 
CD34-LKS long-term hematopoietic stem cells were sorted into one well of a 96 well plate and 
cultured with cytokines favoring cellular proliferation (Figure 2-14a). After seventy-two hours of culture 
approximately fifty-seven of ninety-six wells that originally contained one DNMT3blox/lox ER-Cre+ or 
tamoxifen treated DNMT3blox/lox ER-Cre- cell still contained at least one cell and of these nearly fifty-
eight percent (thirty-three out of fifty seven) contained at least five cells (Figure 2-14b, c). In contrast 
only twenty out of ninety-six wells that originally contained one DNMT3blox/lox ER-Cre+ cell treated with 
tamoxifen still contained one cell after seventy-two hours and the majority of these wells (40.9%) 
contained only one cell (Figure 2-14b,c). This data indicates a proliferative defect at the single cell 
level for highly purified hematopoietic stem cells and provides a potential cellular mechanism for the 
observed defect in stem cell self-renewal observed in vivo. 
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2.3.7 DNMT3b Function in Hematopoietic Cells Requires Its Methyltransferase Activity  
In an attempt to define a molecular mechanism underlying the functional defect in hematopoietic 
stem cells the ability of wild-type DNMT3b, a mutant DNMT3b lacking catalytic activity, and DNMT3a 
to rescue the colony forming ability of DNMT3b hematopoietic cells was analyzed. DNMT3b cells 
transduced with an MSCV vector alone produced significantly fewer colonies in a secondary CFC 
assay as compared to MSCV transduced DNMT3blox/lox cells (Figure 2-15). Only wild-type DNMT3b 
cDNA, and not DNMT3bC657A or wild-type DNMT3a, was able to rescue the colony forming ability of 
DNMT3b cells (Figure 2-15). This data indicates that DNMT3b activity in hematopoietic progenitors 
requires the methyltransferase activity of DNMT3b and DNMT3a can not compensate for DNMT3b 
deletion. 
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2.3.8 Decreased MLL Expression in DNMT3b Cells is Associated with Loss of DNA Methylation  
In order to identify potential targets of DNMT3b methyltransferase activity an analysis of previously 
reported changes in DNA methylation during hematopoiesis[111] was undertaken. It was assumed 
that loss of DNMT3b would lead to a decrease in DNA methylation and, as observed in embryonic 
stem cells, defective DNA methylation would lead to ineffective gene silencing during 
differentiation[2]. Nine potential candidate genes were identified that had highly methylated regions in 
close proximity to their first exon similar to HoxA10 which is highly methylated just 5’ of an associated 
CpG island in its first exon (Figure 2-16). The expression level of Gata2, HoxA6, HoxA9, HoxA10, 
HLF, Meis1, MLL, Prdm16, and Nkx2-3 was determined by quantitative real-time RT-PCR in the 
stem cell enriched LKS bone marrow cells as well as two myeloid progenitor populations, common 
myeloid and granulocyte-monocyte progenitors from DNMT3blox/lox and DNMT3b mice three 
months after tamoxifen induction of DNMT3b recombination. Of these genes HoxA9, HoxA10, Meis1, 
and MLL showed decreased expression in DNMT3b LKS cells as compared to DNMT3blox/lox 
controls (Figure 2-17a). To determine if this decrease in expression was due to changes in DNA 
methylation bisulfite sequencing of highly methylated regions in MLL and HoxA10 was performed in 
whole bone marrow cells. Loss of DNMT3b lead to a decrease in methylation at the MLL locus from 
91.1% to 70.3% while no change was observed in DNA methylation at the HoxA10 locus (Figure 2-
17b). This data implicates MLL as a downstream target of DNMT3b and loss of DNMT3b may in turn 
silence its expression in a hematopoietic stem cell enriched compartment. 
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Figure 2-16. Methylation of HoxA10 in Hematopoietic Progenitors 
Diagram of the methylation at HoxA10 as found by Ji et al [111]. Bottom panel shows the alignment 
of HoxA10 on the negative strand of chromosome 9, the 5’ end of the gene is at the right of the page. 
Grey boxes represent exons and the underlaid white box indicates the coding sequence of the gene. 
The middle panel displays the corresponding CpG density with each horizontal black line indicating 
one CpG and orange bars a potential CpG island. The top panel shows the methylation of each CpG 
for double negative 3 (DN3) T cell precursors, Flk2 negative multipotent progenitors (Flk2_neg_MPP) 
and granulocyte-monocyte progenitors (GMP). There is a high level of DNA methylation just to the 5’ 
end of the first exon of HoxA10. 
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Figure 2-17. DNMT3b Loss Causes a Decrease in MLL Expression Associated with 
Demethylation. 
(a) Expression of DNMT3b, MLL, Meis1, and HoxA10 in hematopoietic stem and progenitor cells of 
DNMT3blox/lox and DNMT3b mice. Expression was measured by quantitative real-time RT-PCR and 
normalization to the level of -actin. LKS, Lineage-c-kit+Sca-1+ stem cell enriched bone marrow; 
CMP, common myeloid progenitors; GMP, granulocyte-monocyte progenitors. (b) Methylation of the 
MLL and HoxA10 locus in whole bone marrow cells from DNMT3blox/lox and DNMT3b mice. The 
percentage of methylated CpGs (black circles) is indicated.  
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2.4 CONCLUSIONS 
 
 
The data presented in this thesis demonstrates that hematopoiesis is dependent upon DNMT3b by a 
cell intrinsic mechanism. Underlying this defect in hematopoiesis is a loss of hematopoietic stem cell 
self-renewal as evidenced by the failure of DNMT3b cells to engraft in secondary recipients. This 
decreased self-renewal is associated with a decreased proliferative capacity at the single cell level in 
vitro as well as increased apoptosis both in vivo and in vitro. While we can not rule out an effect of 
DNMT3b on other hematopoietic stem cell functions such as homing or retention within the bone 
marrow niche the presence of equivalent engraftment to control cells after one month of 
transplantation make a role for DNMT3b in hematopoietic stem cell homing or retention in the bone 
marrow unlikely.  
DNMT3b may also play a cell extrinsic role in maintenance hematopoietic stem cells by 
regulating the hematopoietic stem cell niche. Irradiation of the bone marrow can induce expansion of 
transplanted cells and this, rather than a lack of space within the marrow in non-ablated recipients, 
may cause the enhanced engraftment of transplanted bone marrow in irradiated recipients[143]. In 
addition radiation has been shown to induce changes in the expression of the de novo 
methyltransferases DNMT3a and DNMT3b[144], and the former of the two may mediate bystander 
effects following irradiation[145]. Loss of DNMT1 has also been shown to enhance both whole bone 
marrow and hematopoietic stem cell engraftment in the setting of non-ablative transplantation[5]. 
Thus depletion of DNMT3b from the hematopoietic niche in the bone marrow or spleen may account 
for the observed expansion of white blood cells in the peripheral blood (Figure 2-8e).  
A defined role for DNMT1 in hematopoietic cells remains obscure[5, 6]. While Broske et al 
demonstrated frank bone marrow failure in the absence of DNMT1[6] and Trowbridge et al found no 
effect of DNMT1 loss on hematopoietic cells under homeostatic conditions[5] both studies 
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demonstrated limited engraftment in irradiated hosts following loss of DNMT1. In both studies this 
was associated with a more profound effect on hematopoietic progenitors (LKS- cells) as opposed to 
more immature stem cell populations and neither assessed the role of DNM1 at the single cell level in 
hematopoietic stem or progenitor cells[5, 6]. Thus DNMT3b may play a specific role in the 
maintenance of DNA methylation in hematopoietic stem cells that is unique from DNMT1 which is 
considered a maintenance methyltransferase. Moreover these studies failed to identify changes in 
expression of genes associated with hematopoietic stem cell function and alterations in DNA 
methylation. This may be due to the fact that gene expression changes in these studies were 
assessed within four days of induction of DNMT1 loss and a passive mechanism of DNA 
demethylation may have not led to changes in gene expression within this time frame.  
The function of DNMT3b within hematopoietic stem cells appears to require the 
methyltransferase activity of DNMT3b, and not DNMT3a, and a decrease in methylation of MLL, 
leading to its loss of expression, may underlie this defect. Our data suggests a model whereby 
DNMT3b is necessary to maintain the expression of MLL in hematopoietic stem cells. Although 
numerous mechanisms have been identified by which active, i.e. enzyme mediated, DNA 
methylation may occur[146], the assessed MLL locus remains methylated throughout progenitor 
development [111] and down-regulation of its expression during hematopoietic differentiation does 
not appear to be correlated with decreased levels of DNA methylation. It is likely then that the 
observed demethylation occurs through a passive process during hematopoietic stem cell division in 
the absence of DNMT3b, similar to a proposed role for DNMT3b in certain cancer cells[124] and 
embryonic stem cells[2]. With each division the degree of methylation becomes less due to a failure 
of DNMT3b to methylate the daughter DNA strand. Thus individual bisulfite-treated clones with a 
relatively high level of methylation may represent cells derived from hematopoietic stem cells that 
have undergone fewer cell divisions. It is likely that DNA methylation itself, and not the level of 
DNMT3b, determines the phenotype of DNMT3bcells. A similar mechanism of gene regulation 
was observed in neural precursor cells in the absence of DNMT3a; changes in the methylation of the 
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gene and not its occupancy by DNMT3a were correlated with changes in gene expression[110]. 
Moreover as this process is passive and requires cell division, conditions which enhance cell division 
would elicit a more dramatic phenotype from DNMT3b cells. This may explain while transplantation 
into irradiated mice yielded enhanced hematopoietic stem cell defictis following DNMT3b deletion 
than under homeostatic conditions where the replicative demands on hematopoietic stem cells are 
limited.  
Conditional deletion of MLL produces a similar phenotype observed in this study. MLL 
deletion leads to a loss of hematopoietic cells in bone marrow chimeras and decreased proliferation 
of myeloid progenitors[85]. In another study MLL deletion lead to normal hematopoiesis under 
homeostatic conditions but defective engraftment in irradiated recipients[86]. However it is difficult to 
determine the kinetics by which demethylation of the MLL locus effects its expression, ie the point at 
which loss of methylation induces changes in MLL expression that has a functional impact on 
hematopoietic stem cell function. The homeobox proteins HoxA9 and HoxA10 have been shown to 
regulated by MLL in hematopoietic cells[85, 87, 147] and loss of HoxA gene expression may underlie 
the observed hematopoietic defect following DNMT3b deletion. Interestingly MLL is a H3K4 
methyltransferase, the permissive histone modification that was shown to lost in the absence of 
DNMT3a in neural progenitor cells[110], underscoring an interplay between DNA methylation and 
histone modifications during hematopoiesis. Further investigation of the genetic programs regulated 
by DNA methylation in hematopoietic stem cells may yield potential targets for therapeutic 
manipulation of these cells. 
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2.5 FUTURE STUDIES 
 
 
A role for DNMT3b in the hematopoietic niche is suggested by the increased number of white blood 
cells in the peripheral blood of mice lacking DNMT3b under homeostatic conditions (Figure 2-8e) and 
increased engraftment of wild-type bone marrow under non-ablative conditions in DNMT1-null 
mice[5]. Therefore it would be interesting to determine a role for DNMT3b in the hematopoietic niche 
by transplantation of wild-type bone marrow cells into DNMT3b recipient mice without pre-
conditioning with irradiation. This work may also be extended to transplantation in the setting of 
irradiation given that the de novo methyltransferases appear to mediate bystander effects in other cell 
types following irradiation[145].  
A previous study analyzing changes in DNA methylation during hematopoiesis relied on a 
microarray platform of isolated CpG islands[111]. However regions of differential methylated between 
cell types may actually lie outside of these islands, at CpG shores[108, 110]. Therefore an unbiased 
assessment of changes in DNA methylation during hematopoiesis is warranted. Also the analysis of 
the genes identified by Ji et al indicates that the areas of high levels of DNA methylation may 
maintain that level of methylation during hematopoietic development, as is seen for HoxA10 (Figure 
2-16), and down regulation of gene expression may not be associated with changes in DNA 
methylation. Thus it may be more worthwhile to examine genome-wide changes in methylation 
following disruption of one or more of the DNA methyltransferases within the hematopoietic stem cell 
compartment in order to determine the regions that may be important for gene expression but are not 
necessarily altered during its silencing. 
A complete assessment of the role DNA methylation plays in regulation of MLL expression 
and subsequently in hematopoietic stem cell function is difficult. One method to define MLL role’s 
would be a rescue experiment to determine if MLL can restore hematopoietic engraftment following 
loss of DNMT3b. However overexpression of MLL in progenitor populations can lead to 
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immortalization [148] indicating that any experiments involving introduction of MLL would require tight 
regulation of its expression. Changes in gene expression following loss of methylation may be 
achieved by MLL promoter constructs driving luciferase expression, however an interplay between 
DNA methylation and histone modifications likely exists, such that it would be necessary to transfect 
cells with a nucleosomal rather than naked DNA.  
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